● Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Condition: Refractory Cancer · Recurrent Cancer · Solid Tumor, Adult · Sponsor: Immatics US, Inc.

PhasePhase 1/Phase 2

Planned participants375

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

This description comes directly from the study's public registry record.

Talk to the study team

Immatics US, Inc. · +1 346 204-5400 · ctgovinquiries@immatics.com

Always discuss trial participation with your own doctor first.

Locations (21)

Stanford Cancer Institute	Stanford, California, United States	Recruiting
University of Colorado, Anschutz Medical Campus	Aurora, Colorado, United States	Recruiting
University of Miami Hospital and Clinics	Miami, Florida, United States	Recruiting
University of Chicago Medical Center	Chicago, Illinois, United States	Recruiting
Massachusetts General Hospital	Boston, Massachusetts, United States	Recruiting
Memorial Sloan Kettering Cancer Center	New York, New York, United States	Recruiting
Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run	Columbus, Ohio, United States	Recruiting
University of Pennsylvania, Perelamn Center for Advanced Medicine	Philadelphia, Pennsylvania, United States	Recruiting
Thomas Jefferson University, Honickman Center	Philadelphia, Pennsylvania, United States	Recruiting
Fox Chase Cancer Center	Philadelphia, Pennsylvania, United States	Recruiting
University of Pittsburgh Medical Center	Pittsburgh, Pennsylvania, United States	Recruiting
University of Texas MD Anderson Cancer Center	Houston, Texas, United States	Recruiting

+ 9 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03686124